High-Intensity Alternating Current Stimulation as an Add-On to Multidisciplinary Intensive Rehabilitation for Parkinson's Disease: A Randomized Controlled Trial

高强度交流电刺激作为帕金森病多学科强化康复的辅助疗法:一项随机对照试验

阅读:1

Abstract

AIMS: In this randomized, double-blind, sham-controlled trial, we explored whether high-intensity transcranial alternating current stimulation (Hi-tACS), as an add-on to multidisciplinary intensive rehabilitation therapy (MIRT), could yield more durable quality of life (QoL) improvements than MIRT alone. METHODS: Sixty patients with Parkinson's disease (PwP) (Hoehn and Yahr stages 1-3, aged 45-70) were assigned (1:1) to receive 10 days of MIRT with either twice-daily Hi-tACS (15 mA, 77.5 Hz, 40 min/session) or sham stimulation. The primary outcome was the longitudinal change in the 39-item Parkinson's Disease Questionnaire (PDQ-39) total score from baseline to 4, 12, and 24 weeks after intervention. Secondary outcomes included changes in motor and non-motor symptom scales. Adverse events were monitored throughout the intervention period. RESULTS: Generalized estimating equation analysis revealed a significant group-by-time interaction for PDQ-39 total scores (P(group × time) = 0.008). The Hi-tACS+MIRT group demonstrated significantly greater reductions in PDQ-39 scores than the sham-Hi-tACS+MIRT group at 4 weeks (T2: effect size = 0.68, 95% CI: 0.14-1.21; P(FDR) = 0.009), 12 weeks (T3: effect size = 1.43, 95% CI: 0.80-2.05; P(FDR) = 0.003), and 24 weeks (T4: effect size = 1.26, 95% CI: 0.65-1.85; P(FDR) < 0.001). In addition, the Hi-tACS+MIRT group exhibited superior improvements in depression and apathy. Adverse events were mild and infrequent, with no serious adverse events reported. CONCLUSIONS: This trial demonstrated that the Hi-tACS add-on to MIRT could maintain long-term improvements in QoL and improve non-motor symptoms for PwP, providing a new strategy for PwP rehabilitation.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。